Press release 14-12-2018

Biotype Diagnostic develops a novel test for diagnosing fungi in the joint project InfectControl 2020 FINAR

Within the InfectControl 2020 FINAR BMBF-project the selection for resistances is captured for the first time systematically by specialists coming from the fields of phytopathology, veterinary medicine and infection biology. Furthermore, the clinical relevance of resistances is analyzed in depth and strategies are developed to prevent their spread. Already a new diagnostic test was developed on the basis of this data, in cooperation with Biotype Diagnostic GmbH permitting a rapid detection of fungal infections (especially Aspergillus fumigatus) and clinically relevant resistances.

FINAR is an example of a successful project, which allows for the advancement of technology developments powered by a nationwide interdisciplinary team consisting of academic and commercial partners. One patent application has already been filed by the biotech company Biotype Diagnostic and more will follow.

As a flagship project of InfectControl 2020, FINAR will move on to the second round of funding in April 2019. New opportunities present themselves within this synergistically planned project to establish this technology as a real-time PCR on Biotypes proprietary Modaplex PCR platform. Additionally, improvements in the pre-analytic of the “liquid biopsies” are targeted. Clinical validation studies of the laboratory tests, detecting relevant fungal pathogens in blood, will complete the FINAR project.

Participating parties:

  • Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute (Jena, coordinator)
  • Martin-Luther University Halle-Wittenberg
  • University Leipzig
  • Biotype Diagnostic GmbH (Dresden)

Video about InfectControl 2020 FINAR